Last reviewed · How we verify
Liposome-encapsulated SN38
At a glance
| Generic name | Liposome-encapsulated SN38 |
|---|---|
| Sponsor | INSYS Therapeutics Inc |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (PHASE3)
- A Study of Irinotecan Liposome in Advanced Pancreatic Cancer (PHASE1)
- Evaluation of the Efficacy and Safety of Nal-IRI for Progressing Brain Metastases in Breast Cancer Patients (PHASE2)
- Study of Eryaspase in Combination With Chemotherapy Versus Chemotherapy Alone as 2nd-Line Treatment in PAC (PHASE3)
- Liposomal SN-38 in Treating Patients With Small Cell Lung Cancer (PHASE2)
- Liposome-encapsulated Irinotecan Hydrochloride PEP02 or Irinotecan Hydrochloride, Leucovorin Calcium, and Fluorouracil as Second-Line Therapy in Treating Patients With Metastatic Colorectal Cancer (PHASE2)
- Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Liposome-encapsulated SN38 CI brief — competitive landscape report
- Liposome-encapsulated SN38 updates RSS · CI watch RSS
- INSYS Therapeutics Inc portfolio CI